OpenBench and HemoShear Therapeutics Agree to Pursue Rare Disease Target Using Artificial Intelligence

SAN FRANCISCO: SAN FRANCISCO, Oct. 5, 2021 /PRNewswire/ -- OpenBench, Inc., an emerging leader in AI-enabled small molecule discovery, entered into an agreement with HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, to use the OpenBench virtual screening platform to identify novel, potent inhibitors of an undisclosed rare...

Click to view original post